2010
Personalized approach to prostate cancer prognosis.
Donovan M, Costa J, Cordon-Cardo C. Personalized approach to prostate cancer prognosis. Minerva Urologica E Nefrologica 2010, 62: 231-9. PMID: 20940693.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate needle biopsyNeedle biopsyProstate cancerProstatectomy specimenDiagnostic prostate needle biopsiesSerum prostate-specific antigenPatient-specific risk profileClinical-pathologic variablesExtent of diseaseManagement of patientsAncillary diagnostic studiesTreatment decision processPrognostic featuresTumor differentiationBreast cancerIndividual patientsCancer prognosisSpecific antigenClinical judgmentHealth outcomesMost urologistsTumor typesClinical decisionPatient attributes
1988
Interdisciplinary detection of soft tissue sarcomas. Diagnosis, grading and staging.
Leyvraz S, Costa J. Interdisciplinary detection of soft tissue sarcomas. Diagnosis, grading and staging. Die Orthopädie 1988, 17: 121-7. PMID: 3290794.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasTissue sarcomasDifferent prognostic factorsManagement of patientsStratification of patientsPrognostic factorsSimilar prognosisSurgical marginsHistological diagnosisStaging systemClinical aspectsOptimal diagnosisTumorsPatientsDiagnosisPrognosisSarcomaStagingCliniciansPathologistsGradingHistological diagnosis and grading of soft‐tissue sarcomas
Leyvraz S, Costa J. Histological diagnosis and grading of soft‐tissue sarcomas. Journal Of Surgical Oncology 1988, 4: 3-6. PMID: 3353621, DOI: 10.1002/ssu.2980040103.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasMalignant lesionsGrade 2Management of patientsHigh-grade lesionsLow-grade lesionsHistopathological differential diagnosisGrade 2 lesionsSoft tissue tumorsBasis of hematoxylinEosin-stained sectionsNational Cancer InstituteConventional special stainsLesions recurLocal recurrenceInitial diagnosisHistological diagnosisHistological typingHistological featuresDifferential diagnosisBenign tumorsBiological aggressivenessGrade 3Malignant tumorsCancer Institute